Osimertinib Granted Breakthrough Therapy Designation for First-Line Treatment of EGFR Mutation–Positive NSCLC – The ASCO Post

  There is a new breakthrough therapy granted by the FDA for Osimertinib as first-line treatment for patients with EGFR positive metastatic NSCLC! Quelle: Osimertinib Granted Breakthrough Therapy Designation for First-Line Treatment of EGFR Mutation–Positive NSCLC – The ASCO Post

Read More Osimertinib Granted Breakthrough Therapy Designation for First-Line Treatment of EGFR Mutation–Positive NSCLC – The ASCO Post

The ASCO Post – Cancers Associated With Overweight and Obesity Make Up 40% of Cancers Diagnosed in the United States

Dear blog readers, did you know that being overweight is associated with some cancers? “The International Agency for Research on Cancer (IARC) has identified 13 cancers associated with overweight and obesity: meningioma; multiple myeloma; adenocarcinoma of the esophagus; and cancers of the thyroid, postmenopausal breast, gallbladder, stomach, liver, pancreas, kidney, ovaries, uterus, and colon or […]

Read More The ASCO Post – Cancers Associated With Overweight and Obesity Make Up 40% of Cancers Diagnosed in the United States

For Relapsed or Refractory Multiple Myeloma

  FDA Approves Daratumumab in Combination With Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma – The ASCO Post New treatment strategies available for patients with multiple myeloma who have received at least one prior therapy. Daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone has been FDA approved.   Quelle: FDA […]

Read More For Relapsed or Refractory Multiple Myeloma

The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme. – PubMed – NCBI

Glioblastoma is the most progressive brain tumor with a dismal prognosis. One strategy is to target a novel and highly specific tumor antigen, EGFR variant III. This tumor antigen is present in approx. a third of all patients with GBM and is exclusively expressed on tumor tissue cells. Eur J Pharmacol. 2017 Sep 5;810:70-82. doi: […]

Read More The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme. – PubMed – NCBI